ALTIMMUNE (ALT)
$5.58
0.01 (0.18%)
ALT Stock Quote Delayed 30 Minutes
3 Promising Biotech Stocks for the Long-Term: August 2024
Some of the best biotech opportunities can be found in oversold obesity treatment stocks. Here are just a few.
Louis Navellier's Total Grade
Powered by Portfolio Grader?
Unlock Louis Navellier's
? Stock Report – FREE:
Is ? a BUY?
Powered by Portfolio Grader
A
B
C
D
F
?
Unlock Louis Navellier's
? Stock Report to Find Out – FREE:
Louis Navellier's Total Grade
Powered by Portfolio Grader?
Investing legend Louis Navellier rates ? a "?." Unlock his ? Stock Analysis to find out why – FREE:
Louis Navellier's Total Grade
Powered by Portfolio Grader?
Fundamental Grade
Quantitative Grade
- Sales Growth ?
- Operating Margin Growth ?
- Earnings Growth ?
- Earnings Momentum ?
- Earnings Surprises ?
- Analyst Earnings Revisions ?
- Cash Flow ?
- Return on Equity ?
Previous Close
$5.59
Market Cap
428.97M
PE Ratio
-4.17
EPS
-1.3388
Volume (Avg. Vol.)
2.37M
Day's Range
$5.46 - $5.64
52-Week Range
$5.28 - $11.50
Dividend & Yield
N/A (N/A)
ALT Stock Predictions, Articles, and ALTIMMUNE News
Forget Boring Diversification! 3 Wild-Card Stocks to Spice Up Your Portfolio
These three wild-card stocks will spice up your portfolio in ways boring diversification never could, so read on.
7 Bullish Stock Picks With the Potential to Turn $5K Into $50K
These high-potential stock picks each have 10X potential moving forward and are well worth understanding despite high prices in some cases.
The 7 Best Under $10 Stocks to Buy in July 2024
We’re finding big opportunities in some of the best stocks under $10 a share. In fact, here are seven you may want to jump into now.
The 3 Smartest Biotech Stocks to Buy With $5K Right Now
With global obesity numbers bursting at the seams, some of the smartest biotech stocks to buy are those with weight loss drugs.
ALT Stock Alert: Altimmune Pops on Weight-Loss Drug Findings
Altimmune (ALT) stock is soaring and trending after the company reported data on its GLP-1 weight-loss drug today.
ALT Stock Earnings: Altimmune Beats EPS for Q1 2024
ALT stock results show that Altimmune beat analyst estimates for earnings per share the first quarter of 2024.
ALT Stock Earnings: Altimmune Beats EPS for Q4 2023
ALT stock results show that Altimmune beat analyst estimates for earnings per share the fourth quarter of 2023.
Why Is Altimmune (ALT) Stock Up 14% Today?
Altimmune stock is rising higher on Monday as ALT investors react to positive news from rival weight loss drugmaker Zealand Pharma.
Kerrisdale Capital Slams Altimmune (ALT) Stock in New Short Report
Kerrisdale Capital has released a short report, making clear why it is betting against ALT stock. Here's why Altimmune is likely in trouble.
